临床试验/NCT02459067

NCT02459067终止2 期

Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

TC Biopharm7 个研究点分布在 1 个国家目标入组 8 人开始时间: 2015年12月最近更新: 2022年3月10日

适应症

试验速览

阶段: 2 期
状态: 终止
发起方: TC Biopharm
入组人数: 8
试验地点: 7
主要终点: Proportion of patients with drug-related > grade 3 toxicity (except for nausea, vomiting or grade 3 diarrhoea without maximal supportive therapy; anaemia, alopecia, or asymptomatic grade 3 laboratory findings that last for < 7 days)

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.

详细描述

This is an open-label trial of ImmuniCell® treatment of patients with malignant melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC) which are refractory to current treatment or who have indolent disease for which immunotherapy may be beneficial. The trial is designed to identify a safe dose of ImmuniCell® for future clinical trials, to identify a response signal from one or more of the cancers under investigation and to confirm the safety and efficacy in the selected target tumour.

The trial has three stages:

Stage I comprising a safety cohort of patients to identify a safe dose Stage II comprising an expanded patient group for response signal identification Stage III to confirm efficacy and safety.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female patients aged ≥18 years
•Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1
•Subjects with histological or cytological confirmation of advanced malignant melanoma, renal cell carcinoma or NSCLC which are refractory to current standard treatments or who have indolent disease for which immunotherapy may be beneficial
•Measurable disease according to the irRC criteria
•Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted <2 weeks prior to Cycle 1:
•Creatinine ≤ 1.5 x upper limit of normal (ULN) OR a calculated creatinine clearance ≥ 50 ml/min
•Total bilirubin ≤ 1.5 x ULN
•Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN with liver metastases
•Absolute lymphocyte count ≥1.0 x 10E9/L
•Absolute Neutrophil Count (ANC) ≥1.5 x 10E9/L
•Platelets ≥100 x 10E9/L
•Haemoglobin ≥ 10 g/dL
•Life expectancy of at least 3 months
•Suitable increase in starting γδ T cell number to final γδ T cell number in the proliferation assay between 10 days in culture
•Able to give informed, written consent
•For female patients and female partners of male patients: must be surgically sterile, postmenopausal, or compliant with two forms of contraception (one of which must be a barrier method) during and for 6 months after the treatment period; female patients must have a negative urine pregnancy test at screening and must not be breast-feeding.

排除标准

•Other primary cancers apart from non-melanoma skin cancers, carcinoma - in situ of the cervix, or a prior cancer treated with curative intent more than 2 years ago without any evidence or recurrent disease
•Uncontrolled systemic infection
•Systemic steroid therapy or other immune-suppressants (except in cases where the patient is receiving treatment with replacement doses for adrenal insufficiency)
•Treatment with bisphosphonates, for instance zoledronate, in the previous 3 months and throughout the trial
•New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within 6 months
•Clinically-significant uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation not requiring therapy.
•Ulcerative Colitis / Inflammatory bowel disease, Addison's disease
•Pregnancy or lactation before or during the trial. A urine pregnancy test will be carried out at screening
•Taking any other investigational medicinal product (IMP) or participation in another interventional clinical trial in the previous 30 days
•Less than 4 weeks since systemic anti-cancer therapy (tyrosine kinase inhibitors, chemotherapy, immunotherapy, hormonal therapy, radiotherapy) and less than 6 weeks since mitomycin C and nitrosureas
•Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the trial or evaluation of the trial results
•Any other condition considered by a trial physician to be inappropriate for inclusion to the study such as contraindications to leukapheresis (contraindications to heparin which are: recent cerebral haemorrhage; peptic ulcer; recent surgery to eye or nervous system; hypersensitivity to heparin; past history of Type II heparin induced thrombocytopenia; past history of significant spontaneous haemorrhage; known haemophilia or other bleeding disorder).
•Serological evidence of active infection

结局指标

主要结局

Proportion of patients with drug-related > grade 3 toxicity (except for nausea, vomiting or grade 3 diarrhoea without maximal supportive therapy; anaemia, alopecia, or asymptomatic grade 3 laboratory findings that last for < 7 days)

时间窗: 3 months

Document the clinical response (immediate or delayed CR, PR, SD or PD) of the patients following ImmuniCell® treatment and assess the data for a response signal to guide the confirmatory stage

时间窗: 12 months

次要结局

Changes in markers of immune response (such as IFN-γ, IL-2 and TNF-α) before the first and subsequent ImmuniCell® infusions(12 months)
Changes in peripheral T lymphocyte counts before the first and subsequent ImmuniCell® infusions (optional)(12 months)

研究者

发起方

TC Biopharm

申办方类型

Industry

责任方

Sponsor

研究点 (7)

Loading locations...

相似试验

已完成

1 期

AST-021p Study in Advanced Solid TumorsAdvanced Cancer

NCT04864418Aston Sci. Inc.22

招募中

早期 1 期

TCR-T Cells in the Treatment of Advanced Pancreatic CancerPancreatic Cancer

NCT06054984Ruijin Hospital18

已完成

2 期

Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating AdjuvantHay Fever

NCT01506375BioTech Tools S.A.24

已完成

1 期

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite AllergyPerennial Allergic RhinoconjunctivitisAllergic Asthma

NCT00652223Cytos Biotechnology AG21

撤回

1 期

NCT03735589Roswell Park Cancer Institute